...
Semaglutide, the active ingredient in Novo Nordisk's Wegovy and diabetes medicine Ozempic, goes off patent in India in 2026, paving the way for cheaper versions of the drugs.
.jpg&w=3840&q=75)
Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024.
Credit: Reuters/Hollie Adams
